Research

Energy balance

The analysis found no significant differences in efficacy and safety of the drugs between age groups.

Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors appear consistent across age groups.

StrongSupportsmedium confidence
Unsere Analyse fand keine signifikanten Unterschiede in Wirksamkeit und Sicherheit der Wirkstoffe zwischen den Altersgruppen.
Svea Stüdemann et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2025

Why this rating

Based on the analysis of multiple studies.

Source

Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?

Svea Stüdemann et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2025

DOI 10.1055/a-2492-9440

other · n=104
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →